Inclusion Criteria:

- Age > 18 years.

- Advanced cancer potentially sensitive to vinorelbine:

- Breast cancer.

- Stage 3 or 4 non-small cell lung cancer.

- Non-Hodgkins lymphoma.

- Cancer of other histologic type, sensitive to vinca alkaloids.

- Rare tumor type with no standard treatment, for which single agent vinorelbine is
appropriate therapy.

- Failure of standard treatment(s) of the tumor.

- Life expectancy of at least three months.

- ECOG performance level 0-2 or Karnofsky score 100-70.

- Hematological and serum chemistry results with defined ranges.

- Willingness and ability to provide written informed consent.

Exclusion Criteria:

- Pregnancy or lactation. In a woman of childbearing potential, a positive pregnancy
test result, no pregnancy test result, or no use of reliable contraception, at
baseline. A postmenopausal woman will be considered to be of childbearing potential
until there has been amenorrhea for at least 12 consecutive months.

- Previous treatment with vinorelbine or mitomycin.

- Any history suggesting or demonstrating resistance to, lack of response to, or
intolerance of any prior vinca alkaloid treatment.

- Active infection.

- Prior anticancer therapy completed within four weeks prior to the first day of study
treatment.

- Failure to have recovered from any toxicity of previous cancer treatment (patients
with alopecia will not be excluded).

- Participation in another experimental drug study within four weeks prior to the first
day of study treatment.

- Requirement for any concomitant chemotherapeutic agent other than the study
medication.

- Any investigator judgment that the individual would not be an appropriate study
subject.